NovaBay to Present at LD Micro Main Event
December 01 2016 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a
biopharmaceutical company focusing on commercializing its Avenova®
lid and lash hygiene product for the domestic eye care market,
announces that Chairman, President and CEO Mark M. Sieczkarek will
present at the LD Micro Main Event on Wednesday, December 7 at 8:00
a.m. Pacific time (11:00 a.m. Eastern time). The conference is
being held at the Luxe Sunset Hotel in Los Angeles.
Mr. Sieczkarek will be available for one-on-one meetings with
the investment community on Wednesday, December 7. Please contact
LD Micro at www.ldmicro.com/contact if you would like to arrange a
meeting.
A live webcast and a replay of the LD Micro Main Event
presentation will be available on the Company's website at
http://novabay.com/investors/events/.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
Avenova, formulated with Neutrox®, is cleared by the U.S. Food
and Drug Administration (FDA) as a 510(k) medical device. Neutrox
is NovaBay’s commercial name for its proprietary pure hypochlorous
acid. Data from a multicenter clinical study show that Avenova
reduced bacterial load, the underlying cause of blepharitis, on
ocular skin surface by more than 90%. Laboratory tests show that
hypochlorous acid has potent antimicrobial activity in solution yet
is non-toxic to mammalian cells and also neutralizes bacterial
toxins. Avenova is marketed to optometrists and ophthalmologists
throughout the U.S. by NovaBay’s direct salesforce. It is
accessible from more than 90% of retail pharmacies in the U.S.
through agreements with McKesson Corporation, Cardinal Health and
AmeriSource Bergen.
Stay informed on NovaBay's
progress:Download our Mobile InvestorApp from
the Apple Store or Google PlayLike us
on FacebookFollow us on TwitterConnect
with NovaBay on LinkedInJoin us on
Google+Visit NovaBay's Website
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161201005306/en/
NovaBay ContactsFor NovaBay
Avenova purchasing information, please contact:Call us:
1-800-890-0329www.Avenova.comorFrom the
CompanyThomas J. Paulson, 510-899-8809Chief Financial
OfficerContact TomorInvestor
Contact:LHAJody Cain, 310-691-7100Jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024